Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?
about
Brain tumorsRadiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: a review of new avenues in its managementMultimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR ImagingMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsModern brain tumor imagingPET/CT in paediatric malignancies - An updatePathophysiology, diagnosis, and treatment of radiation necrosis in the brainPitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Response criteria for glioma.A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.Diagnostics of cerebral gliomas with radiolabeled amino acids.¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative StudyEvaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.Molecular imaging of gliomas with PET: opportunities and limitations.Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasmsDelayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression.Comparative evaluation of 18F-FDOPA, 13N-AMMONIA, 18F-FDG PET/CT and MRI in primary brain tumors - A pilot study.Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosisKinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats.The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumabComparison between MR Perfusion and 18F-FDG PET in Differentiating Tumor Recurrence from Nonneoplastic Contrast-enhancing TissueComparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studiesDisease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery.Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET.Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patientsDifferentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategiesNeurologic Applications of PET/MR Imaging.Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.A comparison study of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors.Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastomaCT Perfusion Dynamics of Intracranial Tuberculomas.Post-treatment appearances, pitfalls, and patterns of failure in head and neck cancer on FDG PET/CT imaging.
P2860
Q24605136-198374A5-42BC-4220-A1F3-9DA0BFAE39A9Q24634976-67EBC288-ECB7-41D4-8707-9EA53034E1ADQ26796223-D151246B-1EAE-4AF4-B8B6-6CF03161F1A6Q26853516-96C9421C-4C00-4CF0-AB31-CA0EF149D100Q27002344-0441B133-823C-4498-AA2A-63B8D731A29DQ28066175-2C5BEE07-8A88-4F41-9723-451533B984E1Q28083668-6B9A15A3-E4E8-42B8-A3B4-64F93DC4EB6AQ30907831-04B3523C-1996-414A-B6CF-8995DD22E735Q31172444-5701901E-DEFC-4C27-8B49-8C5028DCB000Q33379701-3728616F-01A0-4A37-870C-7802EC57D32AQ33487194-2A6F0691-4F68-4F5C-A28B-CABC45107AE7Q33560943-DD96502A-0A8D-4515-9B65-8E73FC5DD77AQ33704202-B1C26BBB-C961-4F7E-B076-5999E815FDCFQ33894461-5A77347A-90A5-4FEB-B5D6-7A9435C3BE08Q33961188-F5E2410C-2195-4E06-B8F1-67C3D168768AQ34203930-0CB157E3-5A2C-4CED-B16C-6972A6A91DBEQ34369465-DE1841E6-9628-4462-AB85-BCFFBC3C44E2Q34517492-039EE2AD-921F-4EC1-83E8-FC5DB9465933Q35103504-16493D89-4D97-4B8A-95EC-B0B89779FCFAQ35610986-46009181-0D11-4934-BCA4-0F46E63FA7C9Q35943921-7706860E-FE13-4F5A-AAA9-E7800FC2D0F4Q36112565-A43751A9-E670-4C3E-8B00-C47B41B087A8Q36118131-5ADFC83B-A51E-419D-B490-2C225B7F5F3DQ36179310-91F026FF-1BE5-4E6C-9735-62BE2B226844Q36356127-3DAE5713-9D98-4677-9BD9-00A677B8CA44Q36474762-CEC8A87A-54C0-4E27-8ACB-8D99B64596F3Q36539340-66C11342-5A7A-4D02-9FA7-48E7BBF2F7F6Q36926781-00C055D7-ACD5-4AE4-8742-AE04B6E56735Q37109256-F2F2A5BC-078D-4EDE-BF36-C0CD34866FC4Q37182922-AECE1D99-2337-45D4-B957-F779A4186047Q37212449-7B0BF74C-E8F2-4D41-AE7F-EAB89C397743Q38074638-98E3834F-068A-4E13-B379-862058234836Q38846608-576298E2-C8C9-4A73-89DF-5CB268DADDA6Q39051286-5F0B38DB-0451-46C5-A654-8AEFC7006777Q39724277-EA5A0E54-6837-4E91-BD95-6ACAF9C64D05Q39747261-C10EE625-EBA8-4017-B865-D5033199F3C1Q40118689-6FCC3FD2-07BD-459B-A5C7-87ED053E6BD7Q40882104-118B6308-5312-4299-B437-2B707595B1ACQ41636531-7710274C-A8BC-484A-AA5F-D7BC5F14BDD9Q41743777-E06E5A6B-F003-44F7-A987-179E19CD967B
P2860
Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Differentiating recurrent tumo ...... positron emission tomography?
@ast
Differentiating recurrent tumo ...... positron emission tomography?
@en
Differentiating recurrent tumo ...... positron emission tomography?
@nl
type
label
Differentiating recurrent tumo ...... positron emission tomography?
@ast
Differentiating recurrent tumo ...... positron emission tomography?
@en
Differentiating recurrent tumo ...... positron emission tomography?
@nl
prefLabel
Differentiating recurrent tumo ...... positron emission tomography?
@ast
Differentiating recurrent tumo ...... positron emission tomography?
@en
Differentiating recurrent tumo ...... positron emission tomography?
@nl
P2093
P1476
Differentiating recurrent tumo ...... positron emission tomography?
@en
P2093
P304
P577
1998-03-01T00:00:00Z